Clinical observation of electrocardiographic changes in response to taxotere combined with adriamycin treatment for breast cancer

Abstract

Abstract: Objective To study the effects of taxotere and adriamycin based chemotherapy on the electrocardiogram (ECG) of patients with locally advanced or metastatic breast cancer. Methods Chemotherapy combining taxotere (75 mg/m²) and adriamycin (5 mg/m²) once every 3 weeks was performed in 250 patients with locally advanced or metastatic breast cancer. Electrocardiograph was recorded before and after each treatment course for a total of 10 courses. Results After the completion of the 10 treatment courses, 8 (3.2%) patients had accelerated heart rate, 12 presented low voltage of QRS complex in the limb leads, and Q-T interval extension, ST segment depression, T-wave flattening, T-wave inversion occurred in 28, 18, 29, and 12 patients, respectively. The rest patients had no ECG changes. Conclusions Taxotere and adriamycin as antitumor chemotherapeutic drugs may cause toxicity in the heart, and result in pericardial effusion, myocardial injury, chronic myocardial ischemia or hypoxia that may lead to abnormal changes in QRS complex and ST-T segment in ECG.

CLC Number:

R737.9

HUANG Zou-qin¹, LI Huo-xia¹, WANG Jia-li¹, WAN Song-guo². Clinical observation of electrocardiographic changes in response to taxotere combined with adriamycin treatment for breast cancer[J]. Journal of Southern Medical University, 2004, 24(05): 582-583.

References

[1] 徐萌,张积仁,许少珍.阿霉素心脏毒性的发生机制及其防治[J].第一军医大学学报(J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao),2001,21(7):532-4.
[2] 乐颖影,李晓文.阿霉素肾病大鼠外周血白细胞及肾脏糖皮质激素受体的变化[J].第一军医大学学报,2001,21(5):334-5.Le YY, Li XW. Expression of glucocorticoid receptors in peripheral leukocytes and in the kidneys of rats with adriamycin nephrosis[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2001, 21 (5):334-5.
[3] 郑航,罗荣城,尤长宣.长春瑞滨联合异环磷酰胺和顺铂治疗晚期乳腺癌疗效的初步观察[J].第一军医大学学报,2003,23(10):1088-9.Zheng H, Luo RC, You CX. Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003, 23(10): 1088-9.
[4] 郑航,何本夫,罗荣城,等.组织多肽特异性抗原在乳腺癌中的临床研究[J].第一军医大学学报,2003,23(8):823-5.Zheng H, He BF, Luo RC, et al. Clinical study of serum tissue polypeptide-specific antigen in breast cancer [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(8): 823-5.
[5] 张军一,麦国丰,郑航,等.乳腺癌HER2、EGFR表达与生存期的相关性[J].第一军医大学学报,2003,23(10):1090-2.Zhang JY, Mai GF, Zheng H, et al. Association between the survival time and high-expression of EGFR and HER-2 in breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23 (10):1090-2.
[6] 黄宛.临床心电图学[M].第5版,北京:人民卫生出版社.1998.96-7;105-6.
[7] 刘新春,陈玉峰,李德爱.实用抗肿瘤药物治疗学[M].北京:人民卫生出版社.2002.366-7.
[8] 裘雪人,孙定人,喻维新.药师手册[M].第2版,北京:人民军医出版社.1998.430-7.

[1]	LI Xin-an,AN Jing Department of Embryology and Histology,Southern Medical University,Guangzhou 510515,China. Mechanisms of the expression of exogenous genes injected via the mammary duct in rat mammary gland tissue [J]. Journal of Southern Medical University, 2006, 26(12): 1774-.
[2]	WU Wu-jun1,ZENG Jian2,PAN Cheng-en1 1Department of General Surgery,First Hospital of Xi’an Jiaotong University,Xi’an 710061,China;2Department of Gastrointestinal and Glands Surgery,First Affiliated Hospital,Guangxi Medical University,Nanning 530021,China. Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis [J]. Journal of Southern Medical University, 2006, 26(12): 1812-1814.
[3]	KANG Hua-feng,WANG Xi-jing,LIU Xiao-xu,DAI Zhi-jun,XUE Feng-jie,XUE Xing-huan Department of Oncological Surgery,Second Affiliated Hospital,School of Medicine,Xi’an Jiaotong University,Xi’an 710004,China. Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism [J]. Journal of Southern Medical University, 2006, 26(11): 1599-1602.
[4]	LI Gui-ping1, ZHANG Yi-fan2, WANG Yong-xian3 1Departmant of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2Department of Nuclear Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China; 3Radiopharmaceutical Research Center, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. 188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro [J]. Journal of Southern Medical University, 2006, 26(10): 1455-1457.
[5]	. [J]. Journal of Southern Medical University, 2006, 26(09): 1378-1379.
[6]	WANG Xiao-yu1, LIN Shao-qiang2, LI Jun-wu2, Kemmner Wolfgang3, DING Yan-qing4 Department of Obstetrics and Gynecology, First Affiliated Hospital of Ji’nan University1, Department of Microbiology and Immunology of Medical College2, Jinan University, Guangzhou 510630, China; 3Max-Delbrueck Center for Molecular Medicine,Berlin 13125, Germany; 4Institute of Oncology, Southern Medical University, Guangzhou 510515, China. Effect of cell surface sialic acid and their linkages on adhesion of mammary carcinoma cells [J]. Journal of Southern Medical University, 2006, 26(06): 742-746.
[7]	WANG Xiao-bing, YANG Qing-xu, PEI Xiao-juan Department of Pathology, Huizhou Central Hospital, Huizhou 516001, China. Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance [J]. Journal of Southern Medical University, 2006, 26(06): 860-863.
[8]	HU Xiao-qu1,QIN Li1,SU Feng-xi1,YAO He-rui2,CHEN Ji-sheng1,GONG Chang1,GUO Ju-jiang1,YU Feng-yan1,JIA Hai-xia1 1Center of Breast Cancer,2Department of Oncology,Second Hospital of Sun Yat-sen University,Guangzhou 510272,China. Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer [J]. Journal of Southern Medical University, 2006, 26(05): 570-572.
[9]	ZHANG Shu-qun1,ZHANG Shu-hui2,XUE Xin-huan1,WANG Xi-jing1,JIANG Jian-tao1 1Department of Oncology,Second Hospital,Xi’an Jiaotong University,Xi’an 710004,China;2Department of Chemical Engineering,Northwestern Polytechnical University,Xi’an 710072,China. Synergism between a siRNA targeted to survivin and 5-FU in inhibiting MCF-7 cell proliferation in vitro [J]. Journal of Southern Medical University, 2006, 26(03): 251-254.
[10]	FAN Yi-xiang,LUO Rong-Cheng,FANG Yong-Xin,YAN Xiao,Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China. Preparation,quality control and biodistribution of 131I-herceptin in New Zealand rabbits [J]. Journal of Southern Medical University, 2006, 26(03): 361-.
[11]	XU Lei, BAI Zhong-hong, XU Ruan-cheng, YAN Hui, WANG Fang-ju, LUO Rong-cheng Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China;Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications [J]. Journal of Southern Medical University, 2006, 26(02): 231-233.
[12]	TAN Ke, FAN Yi-xiang, MIAO Jing-xia, L(?) Cheng-wei, YAN Xiao, LUO Rong-cheng Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro [J]. Journal of Southern Medical University, 2006, 26(02): 234-236.
[13]	CUI Fei, LUO Rong-cheng, CHEN Jin-zhang, CHEN Bin, HUANG Yu-xian. Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu [J]. Journal of Southern Medical University, 2005, 25(12): 1533-1536.
[14]	LI Rong, ZHENG Hang, LUO Rong-cheng. Cloning and expression of the HER2 gene in MCF-7 cells [J]. Journal of Southern Medical University, 2005, 25(10): 1264-1267.
[15]	ZHENG Hang, LUO Rong-cheng. Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1293-1294,1298.